Key Takeaways
- Cibus reported Q4 2025 financial results and announced progress on its Rice herbicide tolerance program targeting 2027 and 2028 commercial launches in LATAM and USA markets.
- The company executed a non-binding commercialization letter of intent with Interoc in January 2026 to advance Latin America market entry in Ecuador and Colombia.
- Cibus raised $22.3 million in gross proceeds from a public offering in January 2026 to support advancement toward near-term initial revenues.
- The European Union reached political agreement on New Genomic Techniques legislation in December 2025, representing a regulatory milestone for gene editing technologies.
- The company received its first customer payment from the Sustainable Ingredients program in Q4 2025 and was selected as a technology partner in the UK Government's Farming Innovation Programme.
Cibus Q4 2025 Financial Results and Business Update
Cibus, Inc. (Nasdaq: CBUS) announced its financial results for the quarter ended December 31, 2025, highlighting significant progress across its agricultural technology programs. The San Diego-based company develops and licenses plant traits to seed companies using gene editing technologies.
“2025 was a landmark year that validated our technology leadership and strategic vision. Our seven Rice partner customers continue to drive our near-term 2027 and 2028 commercial launch targets in our USA and LATAM geographic markets, which have the potential for more than $200 million annual addressable royalties at peak,” said Peter Beetham, Interim Chief Executive Officer of Cibus.
Rice Program Commercial Progress
The company solidified Rice as its priority pipeline program in 2025, focusing on weed management traits HT1 and HT3. Cibus sees 5-7 million peak addressable acres with over $200 million in annual addressable royalties at peak across target markets.
1 Comment